Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
Background Constipation is a common, distressing complication in patients with cancer receiving palliative care. Elobixibat is a novel inhibitor of the ileal bile acid transporter that is used to treat chronic constipation by stimulating bowel function. However, its efficacy in patients with cancer...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2021-10, Vol.26 (10), p.e1862-e1869 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1869 |
|---|---|
| container_issue | 10 |
| container_start_page | e1862 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 26 |
| creator | Ozaki, Anna Kessoku, Takaomi Kasai, Yuki Takeda, Yuma Okubo, Naoki Iwaki, Michihiro Kobayashi, Takashi Yoshihara, Tsutomu Honda, Yasushi Fuyuki, Akiko Higurashi, Takuma Ishiki, Hiroto Taguri, Masataka Oyamada, Shunsuke Kobayashi, Noritoshi Nakajima, Atsushi Ichikawa, Yasushi |
| description | Background
Constipation is a common, distressing complication in patients with cancer receiving palliative care. Elobixibat is a novel inhibitor of the ileal bile acid transporter that is used to treat chronic constipation by stimulating bowel function. However, its efficacy in patients with cancer has not been examined. This study investigated the drug's effectiveness in patients with cancer with chronic constipation.
Patients and Methods
This prospective‐sampling, single‐center, observational study included hospitalized patients with cancer diagnosed, using the Rome IV criteria, with chronic constipation. Within 2 weeks of hospitalization, each participant was administered elobixibat (5–15 mg) daily until discharge. Spontaneous bowel movements (SBMs), complete spontaneous bowel movements (CSBMs), Bristol stool form scale (BSFS) scores, and the Patient Assessment of Constipation Quality of Life questionnaire (PAC‐QOL) scores were assessed before and after elobixibat administration. We also evaluated the relationship between the amount of food consumed and the SBM frequency.
Results
Among the 83 participants, the mean pre‐ and post‐treatment frequencies of daily SBMs were 0.3 and 1.2 (p |
| doi_str_mv | 10.1002/onco.13879 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8488789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780547292</galeid><sourcerecordid>A780547292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4879-b646c7ea90f46c53ce5fd95ae967cf4be3bbeed7485646852e6e3b048e00b8ac3</originalsourceid><addsrcrecordid>eNp9kVFrFDEUhQdRbK2--AMk4IsUZpuZSTbJi7AMWy0UV0TBt5DJ3OxGZ5I1yW67_96sU4uFInnIyc13T244RfG6wrMK4_rCO-1nVcOZeFKcVpSIkgj8_WnWmDclq6g4KV7E-APjLJv6eXHSkIpjLMRpkZaD7-yt7VRCS2NAJ7uH4YC-wGBhDxG1m-Cd1aj1Lia7Vcl6h6xDn7MClyK6sWmDWuU0hNy1VqEfIEbkDUobQIvR71w6ni6979GVS-onvCyeGTVEeHW3nxXfLpdf24_l9erDVbu4LjXJnym7OZlrBkpgkwVtNFDTC6pAzJk2pIOm6wB6RjjNJKc1zHMJEw4Yd1zp5qx4P_lud90Ivc7zBjXIbbCjCgfplZUPb5zdyLXfS044Z1xkg3d3BsH_2kFMcrRRwzAoB34XZU0JFZyxCmf07YSu1QDSOuOzoz7icsE4poTVos7U7BEqrx5Gq70DY3P9QcP51KCDjzGAuZ--wvKYvjymL_-kn-E3__73Hv0bdwaqCbjJzxz-YyVXn9rVZPob3-a8WQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545987710</pqid></control><display><type>article</type><title>Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake</title><source>MEDLINE</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Ozaki, Anna ; Kessoku, Takaomi ; Kasai, Yuki ; Takeda, Yuma ; Okubo, Naoki ; Iwaki, Michihiro ; Kobayashi, Takashi ; Yoshihara, Tsutomu ; Honda, Yasushi ; Fuyuki, Akiko ; Higurashi, Takuma ; Ishiki, Hiroto ; Taguri, Masataka ; Oyamada, Shunsuke ; Kobayashi, Noritoshi ; Nakajima, Atsushi ; Ichikawa, Yasushi</creator><creatorcontrib>Ozaki, Anna ; Kessoku, Takaomi ; Kasai, Yuki ; Takeda, Yuma ; Okubo, Naoki ; Iwaki, Michihiro ; Kobayashi, Takashi ; Yoshihara, Tsutomu ; Honda, Yasushi ; Fuyuki, Akiko ; Higurashi, Takuma ; Ishiki, Hiroto ; Taguri, Masataka ; Oyamada, Shunsuke ; Kobayashi, Noritoshi ; Nakajima, Atsushi ; Ichikawa, Yasushi</creatorcontrib><description>Background
Constipation is a common, distressing complication in patients with cancer receiving palliative care. Elobixibat is a novel inhibitor of the ileal bile acid transporter that is used to treat chronic constipation by stimulating bowel function. However, its efficacy in patients with cancer has not been examined. This study investigated the drug's effectiveness in patients with cancer with chronic constipation.
Patients and Methods
This prospective‐sampling, single‐center, observational study included hospitalized patients with cancer diagnosed, using the Rome IV criteria, with chronic constipation. Within 2 weeks of hospitalization, each participant was administered elobixibat (5–15 mg) daily until discharge. Spontaneous bowel movements (SBMs), complete spontaneous bowel movements (CSBMs), Bristol stool form scale (BSFS) scores, and the Patient Assessment of Constipation Quality of Life questionnaire (PAC‐QOL) scores were assessed before and after elobixibat administration. We also evaluated the relationship between the amount of food consumed and the SBM frequency.
Results
Among the 83 participants, the mean pre‐ and post‐treatment frequencies of daily SBMs were 0.3 and 1.2 (p < .0001) and those of CSBMs were 0.1 and 0.6 (p < .0001), respectively. The mean pretreatment BSFS score was 1.6, whereas the post‐treatment value was 3.5 (p < .0001); the mean PAC‐QOL score (overall) improved from 1.01 to 0.74 (p = .01). There was no significant change in the daily SBM frequency between fasting and feeding states (1.2 vs. 1.3; p = .8), and there was no correlation between the amount of food intake and the SBM frequency after elobixibat administration (r = .03). Serious adverse events were not observed.
Conclusion
This study showed that elobixibat is safe and effective for patients with cancer with chronic constipation, regardless of the food intake amount.
Implications for Practice
Elobixibat was effective at relieving chronic constipation in patients with various cancers. Serious adverse events were not observed, and the relief of constipation was independent of variation in food intake.
Constipation is a common, distressing complication in cancer patients receiving palliative care. This study investigated the effectiveness of elobixibat in cancer patients with chronic constipation.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1002/onco.13879</identifier><identifier>PMID: 34180099</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Bile acids ; Cancer ; Cancer patients ; Care and treatment ; Constipation ; Constipation - drug therapy ; Constipation - etiology ; Demographic aspects ; Diagnosis ; Dipeptides ; Dosage and administration ; Drug therapy ; Eating ; Elobixibat ; Enzyme inhibitors ; Food and nutrition ; Hospital patients ; Humans ; Ileal bile acid transporter ; Linaclotide ; Lubiprostone ; Medical research ; Medicine, Experimental ; Neoplasms - complications ; Palliative care ; Palliative treatment ; Prospective Studies ; Quality of Life ; Symptom Management and Supportive Care ; Testing ; Thiazepines</subject><ispartof>The oncologist (Dayton, Ohio), 2021-10, Vol.26 (10), p.e1862-e1869</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of AlphaMed Press.</rights><rights>2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.</rights><rights>COPYRIGHT 2021 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4879-b646c7ea90f46c53ce5fd95ae967cf4be3bbeed7485646852e6e3b048e00b8ac3</citedby><cites>FETCH-LOGICAL-c4879-b646c7ea90f46c53ce5fd95ae967cf4be3bbeed7485646852e6e3b048e00b8ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488789/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488789/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,27924,27925,45574,45575,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34180099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozaki, Anna</creatorcontrib><creatorcontrib>Kessoku, Takaomi</creatorcontrib><creatorcontrib>Kasai, Yuki</creatorcontrib><creatorcontrib>Takeda, Yuma</creatorcontrib><creatorcontrib>Okubo, Naoki</creatorcontrib><creatorcontrib>Iwaki, Michihiro</creatorcontrib><creatorcontrib>Kobayashi, Takashi</creatorcontrib><creatorcontrib>Yoshihara, Tsutomu</creatorcontrib><creatorcontrib>Honda, Yasushi</creatorcontrib><creatorcontrib>Fuyuki, Akiko</creatorcontrib><creatorcontrib>Higurashi, Takuma</creatorcontrib><creatorcontrib>Ishiki, Hiroto</creatorcontrib><creatorcontrib>Taguri, Masataka</creatorcontrib><creatorcontrib>Oyamada, Shunsuke</creatorcontrib><creatorcontrib>Kobayashi, Noritoshi</creatorcontrib><creatorcontrib>Nakajima, Atsushi</creatorcontrib><creatorcontrib>Ichikawa, Yasushi</creatorcontrib><title>Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Background
Constipation is a common, distressing complication in patients with cancer receiving palliative care. Elobixibat is a novel inhibitor of the ileal bile acid transporter that is used to treat chronic constipation by stimulating bowel function. However, its efficacy in patients with cancer has not been examined. This study investigated the drug's effectiveness in patients with cancer with chronic constipation.
Patients and Methods
This prospective‐sampling, single‐center, observational study included hospitalized patients with cancer diagnosed, using the Rome IV criteria, with chronic constipation. Within 2 weeks of hospitalization, each participant was administered elobixibat (5–15 mg) daily until discharge. Spontaneous bowel movements (SBMs), complete spontaneous bowel movements (CSBMs), Bristol stool form scale (BSFS) scores, and the Patient Assessment of Constipation Quality of Life questionnaire (PAC‐QOL) scores were assessed before and after elobixibat administration. We also evaluated the relationship between the amount of food consumed and the SBM frequency.
Results
Among the 83 participants, the mean pre‐ and post‐treatment frequencies of daily SBMs were 0.3 and 1.2 (p < .0001) and those of CSBMs were 0.1 and 0.6 (p < .0001), respectively. The mean pretreatment BSFS score was 1.6, whereas the post‐treatment value was 3.5 (p < .0001); the mean PAC‐QOL score (overall) improved from 1.01 to 0.74 (p = .01). There was no significant change in the daily SBM frequency between fasting and feeding states (1.2 vs. 1.3; p = .8), and there was no correlation between the amount of food intake and the SBM frequency after elobixibat administration (r = .03). Serious adverse events were not observed.
Conclusion
This study showed that elobixibat is safe and effective for patients with cancer with chronic constipation, regardless of the food intake amount.
Implications for Practice
Elobixibat was effective at relieving chronic constipation in patients with various cancers. Serious adverse events were not observed, and the relief of constipation was independent of variation in food intake.
Constipation is a common, distressing complication in cancer patients receiving palliative care. This study investigated the effectiveness of elobixibat in cancer patients with chronic constipation.</description><subject>Bile acids</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Care and treatment</subject><subject>Constipation</subject><subject>Constipation - drug therapy</subject><subject>Constipation - etiology</subject><subject>Demographic aspects</subject><subject>Diagnosis</subject><subject>Dipeptides</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Eating</subject><subject>Elobixibat</subject><subject>Enzyme inhibitors</subject><subject>Food and nutrition</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Ileal bile acid transporter</subject><subject>Linaclotide</subject><subject>Lubiprostone</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Neoplasms - complications</subject><subject>Palliative care</subject><subject>Palliative treatment</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Symptom Management and Supportive Care</subject><subject>Testing</subject><subject>Thiazepines</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp9kVFrFDEUhQdRbK2--AMk4IsUZpuZSTbJi7AMWy0UV0TBt5DJ3OxGZ5I1yW67_96sU4uFInnIyc13T244RfG6wrMK4_rCO-1nVcOZeFKcVpSIkgj8_WnWmDclq6g4KV7E-APjLJv6eXHSkIpjLMRpkZaD7-yt7VRCS2NAJ7uH4YC-wGBhDxG1m-Cd1aj1Lia7Vcl6h6xDn7MClyK6sWmDWuU0hNy1VqEfIEbkDUobQIvR71w6ni6979GVS-onvCyeGTVEeHW3nxXfLpdf24_l9erDVbu4LjXJnym7OZlrBkpgkwVtNFDTC6pAzJk2pIOm6wB6RjjNJKc1zHMJEw4Yd1zp5qx4P_lud90Ivc7zBjXIbbCjCgfplZUPb5zdyLXfS044Z1xkg3d3BsH_2kFMcrRRwzAoB34XZU0JFZyxCmf07YSu1QDSOuOzoz7icsE4poTVos7U7BEqrx5Gq70DY3P9QcP51KCDjzGAuZ--wvKYvjymL_-kn-E3__73Hv0bdwaqCbjJzxz-YyVXn9rVZPob3-a8WQ</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Ozaki, Anna</creator><creator>Kessoku, Takaomi</creator><creator>Kasai, Yuki</creator><creator>Takeda, Yuma</creator><creator>Okubo, Naoki</creator><creator>Iwaki, Michihiro</creator><creator>Kobayashi, Takashi</creator><creator>Yoshihara, Tsutomu</creator><creator>Honda, Yasushi</creator><creator>Fuyuki, Akiko</creator><creator>Higurashi, Takuma</creator><creator>Ishiki, Hiroto</creator><creator>Taguri, Masataka</creator><creator>Oyamada, Shunsuke</creator><creator>Kobayashi, Noritoshi</creator><creator>Nakajima, Atsushi</creator><creator>Ichikawa, Yasushi</creator><general>John Wiley & Sons, Inc</general><general>Oxford University Press</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202110</creationdate><title>Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake</title><author>Ozaki, Anna ; Kessoku, Takaomi ; Kasai, Yuki ; Takeda, Yuma ; Okubo, Naoki ; Iwaki, Michihiro ; Kobayashi, Takashi ; Yoshihara, Tsutomu ; Honda, Yasushi ; Fuyuki, Akiko ; Higurashi, Takuma ; Ishiki, Hiroto ; Taguri, Masataka ; Oyamada, Shunsuke ; Kobayashi, Noritoshi ; Nakajima, Atsushi ; Ichikawa, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4879-b646c7ea90f46c53ce5fd95ae967cf4be3bbeed7485646852e6e3b048e00b8ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bile acids</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Care and treatment</topic><topic>Constipation</topic><topic>Constipation - drug therapy</topic><topic>Constipation - etiology</topic><topic>Demographic aspects</topic><topic>Diagnosis</topic><topic>Dipeptides</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Eating</topic><topic>Elobixibat</topic><topic>Enzyme inhibitors</topic><topic>Food and nutrition</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Ileal bile acid transporter</topic><topic>Linaclotide</topic><topic>Lubiprostone</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Neoplasms - complications</topic><topic>Palliative care</topic><topic>Palliative treatment</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Symptom Management and Supportive Care</topic><topic>Testing</topic><topic>Thiazepines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozaki, Anna</creatorcontrib><creatorcontrib>Kessoku, Takaomi</creatorcontrib><creatorcontrib>Kasai, Yuki</creatorcontrib><creatorcontrib>Takeda, Yuma</creatorcontrib><creatorcontrib>Okubo, Naoki</creatorcontrib><creatorcontrib>Iwaki, Michihiro</creatorcontrib><creatorcontrib>Kobayashi, Takashi</creatorcontrib><creatorcontrib>Yoshihara, Tsutomu</creatorcontrib><creatorcontrib>Honda, Yasushi</creatorcontrib><creatorcontrib>Fuyuki, Akiko</creatorcontrib><creatorcontrib>Higurashi, Takuma</creatorcontrib><creatorcontrib>Ishiki, Hiroto</creatorcontrib><creatorcontrib>Taguri, Masataka</creatorcontrib><creatorcontrib>Oyamada, Shunsuke</creatorcontrib><creatorcontrib>Kobayashi, Noritoshi</creatorcontrib><creatorcontrib>Nakajima, Atsushi</creatorcontrib><creatorcontrib>Ichikawa, Yasushi</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozaki, Anna</au><au>Kessoku, Takaomi</au><au>Kasai, Yuki</au><au>Takeda, Yuma</au><au>Okubo, Naoki</au><au>Iwaki, Michihiro</au><au>Kobayashi, Takashi</au><au>Yoshihara, Tsutomu</au><au>Honda, Yasushi</au><au>Fuyuki, Akiko</au><au>Higurashi, Takuma</au><au>Ishiki, Hiroto</au><au>Taguri, Masataka</au><au>Oyamada, Shunsuke</au><au>Kobayashi, Noritoshi</au><au>Nakajima, Atsushi</au><au>Ichikawa, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2021-10</date><risdate>2021</risdate><volume>26</volume><issue>10</issue><spage>e1862</spage><epage>e1869</epage><pages>e1862-e1869</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Background
Constipation is a common, distressing complication in patients with cancer receiving palliative care. Elobixibat is a novel inhibitor of the ileal bile acid transporter that is used to treat chronic constipation by stimulating bowel function. However, its efficacy in patients with cancer has not been examined. This study investigated the drug's effectiveness in patients with cancer with chronic constipation.
Patients and Methods
This prospective‐sampling, single‐center, observational study included hospitalized patients with cancer diagnosed, using the Rome IV criteria, with chronic constipation. Within 2 weeks of hospitalization, each participant was administered elobixibat (5–15 mg) daily until discharge. Spontaneous bowel movements (SBMs), complete spontaneous bowel movements (CSBMs), Bristol stool form scale (BSFS) scores, and the Patient Assessment of Constipation Quality of Life questionnaire (PAC‐QOL) scores were assessed before and after elobixibat administration. We also evaluated the relationship between the amount of food consumed and the SBM frequency.
Results
Among the 83 participants, the mean pre‐ and post‐treatment frequencies of daily SBMs were 0.3 and 1.2 (p < .0001) and those of CSBMs were 0.1 and 0.6 (p < .0001), respectively. The mean pretreatment BSFS score was 1.6, whereas the post‐treatment value was 3.5 (p < .0001); the mean PAC‐QOL score (overall) improved from 1.01 to 0.74 (p = .01). There was no significant change in the daily SBM frequency between fasting and feeding states (1.2 vs. 1.3; p = .8), and there was no correlation between the amount of food intake and the SBM frequency after elobixibat administration (r = .03). Serious adverse events were not observed.
Conclusion
This study showed that elobixibat is safe and effective for patients with cancer with chronic constipation, regardless of the food intake amount.
Implications for Practice
Elobixibat was effective at relieving chronic constipation in patients with various cancers. Serious adverse events were not observed, and the relief of constipation was independent of variation in food intake.
Constipation is a common, distressing complication in cancer patients receiving palliative care. This study investigated the effectiveness of elobixibat in cancer patients with chronic constipation.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34180099</pmid><doi>10.1002/onco.13879</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2021-10, Vol.26 (10), p.e1862-e1869 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8488789 |
| source | MEDLINE; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central |
| subjects | Bile acids Cancer Cancer patients Care and treatment Constipation Constipation - drug therapy Constipation - etiology Demographic aspects Diagnosis Dipeptides Dosage and administration Drug therapy Eating Elobixibat Enzyme inhibitors Food and nutrition Hospital patients Humans Ileal bile acid transporter Linaclotide Lubiprostone Medical research Medicine, Experimental Neoplasms - complications Palliative care Palliative treatment Prospective Studies Quality of Life Symptom Management and Supportive Care Testing Thiazepines |
| title | Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A33%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elobixibat%20Effectively%20Relieves%20Chronic%20Constipation%20in%20Patients%20with%20Cancer%20Regardless%20of%20the%20Amount%20of%20Food%20Intake&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Ozaki,%20Anna&rft.date=2021-10&rft.volume=26&rft.issue=10&rft.spage=e1862&rft.epage=e1869&rft.pages=e1862-e1869&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1002/onco.13879&rft_dat=%3Cgale_pubme%3EA780547292%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2545987710&rft_id=info:pmid/34180099&rft_galeid=A780547292&rfr_iscdi=true |